Closing Thoughts on the Future of NSCLC

In their closing remarks, the panel reflects on the presented patient cases and shares insights on the future of non-small cell lung cancer (NSCLC) treatment.

EP: 1.Patient Case 1: A 62-Year-Old Female with NSCLC

EP: 2.Systemic Treatment Options for Non-Small Cell Lung Cancer

EP: 3.Counseling Patients and Caregivers on NSCLC Treatment Toxicities

EP: 4.Patient Case 2: A 45-Year-Old Man with NSCLC Stage IV with Bone and Liver Metastases

EP: 5.Patient Case 3: A 34-Year-Old Non-Smoker with Stage IIIA NSCLC

EP: 6.Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural Metastases

EP: 7.Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC

Now Viewing

EP: 8.Closing Thoughts on the Future of NSCLC

EP: 9.Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC

Recent Videos

Related Content

---

Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC

ONCOLOGY Staff

June 16th 2024

Article

During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.

Related Content

---

Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC

ONCOLOGY Staff

June 16th 2024

Article

During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.